Novo Nordisk A/S Class B Profit Margin

The latest profit margin for NONOF is 37.21% as of March 2026. That compares with 34.51% in the prior-year period — up 7.8% year over year. That is above the Healthcare sector average of 15.58%. Investors often review this figure alongside Novo Nordisk A/S Class B's historical trend and sector peers before judging valuation or financial health.

Over the past year, NONOF's profit margin moved from 34.51% to 37.21% — a 7.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novo Nordisk A/S Class B's valuation or profitability profile.

Against Healthcare companies, NONOF currently prints 37.21% for profit margin, while the sector average sits near 15.58%. That is roughly 138.7% above the sector mean. Large gaps often invite a closer look at Novo Nordisk A/S Class B's growth, margins, and balance sheet.

Profit Margin shows how effectively Novo Nordisk A/S Class B converts resources into returns. At 37.21%, NONOF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 34.51% in the prior-year period — up 7.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NONOF's profit margin (37.21%), review year-over-year change from 34.51%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.